Chen-Pin Wang1, Carlos Lorenzo2, Sara E Espinoza3. 1. Department of Epidemiology & Biostatistics, University of Texas Health Science Center at San Antonio, USA ; Audie L Murphy Veterans Hospital, South Texas Veterans Health Care System, USA. 2. Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, USA. 3. Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, USA ; Department of Medicine, Division of Geriatrics, Gerontology, and Palliative Medicine, University of Texas Health Science Center at San Antonio, USA ; Geriatric Research Education and Clinical Center, Audie L Murphy Veterans Hospital, USA ; Barshop Institute for Longevity and Aging Studies, USA.
Abstract
OBJECTIVE: To determine whether the protective effect of metformin against death is modified by frailty status in older adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted a cohort study during October 1, 1999-September 30, 2006 among veterans aged 65-89 years old with type 2 diabetes but without history of liver, renal diseases, or cancers, who had sulfonylureas or metformin as the sole antidiabetic drug for ≥180 days. The Cox proportional hazard model was used to compare hazard rates of all-cause mortality between the metformin and sulfonylurea users adjusting for the propensity score of metformin use and covariates: age, race/ethnicity, diabetes duration, Charlson comorbidity score, statin use, smoking status, BMI, LDL, and HbA1c. RESULTS: In this cohort of 2,415 veterans, 307 (12.7%) were metformin users, 2,108 (87.3%) were sulfonylurea users, the mean age was 73.7±5.2 years, the mean study period was 5.6±2.3 years, the mean HbA1c at baseline was 6.7±1.0%, 23% had diabetes for ≥10 years, and 43.6% (N=1,048) died during the study period. For patients with and without frailty, the adjusted hazard ratio (HR) of death for metformin vs. sulfonylurea use were 0.92 (95% CI=0.90-1.31, p-value=0.19) and 0.69 (95% CI = 0.60-0.79, p-value<0.001), respectively. Logistic regression analyses showed that metformin (vs. sulfonylurea) was significantly associated with a decreased odds of frailty (OR: 0.66, 95% CI: 0.61-0.71, p-value <.0001). CONCLUSION: Our study suggests that metformin could potentially promote longevity via preventing frailty in older adults with type 2 diabetes.
OBJECTIVE: To determine whether the protective effect of metformin against death is modified by frailty status in older adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted a cohort study during October 1, 1999-September 30, 2006 among veterans aged 65-89 years old with type 2 diabetes but without history of liver, renal diseases, or cancers, who had sulfonylureas or metformin as the sole antidiabetic drug for ≥180 days. The Cox proportional hazard model was used to compare hazard rates of all-cause mortality between the metformin and sulfonylurea users adjusting for the propensity score of metformin use and covariates: age, race/ethnicity, diabetes duration, Charlson comorbidity score, statin use, smoking status, BMI, LDL, and HbA1c. RESULTS: In this cohort of 2,415 veterans, 307 (12.7%) were metformin users, 2,108 (87.3%) were sulfonylurea users, the mean age was 73.7±5.2 years, the mean study period was 5.6±2.3 years, the mean HbA1c at baseline was 6.7±1.0%, 23% had diabetes for ≥10 years, and 43.6% (N=1,048) died during the study period. For patients with and without frailty, the adjusted hazard ratio (HR) of death for metformin vs. sulfonylurea use were 0.92 (95% CI=0.90-1.31, p-value=0.19) and 0.69 (95% CI = 0.60-0.79, p-value<0.001), respectively. Logistic regression analyses showed that metformin (vs. sulfonylurea) was significantly associated with a decreased odds of frailty (OR: 0.66, 95% CI: 0.61-0.71, p-value <.0001). CONCLUSION: Our study suggests that metformin could potentially promote longevity via preventing frailty in older adults with type 2 diabetes.
Entities:
Keywords:
Frailty; Metformin; Mortality; Type 2 diabetes
Authors: Christianne L Roumie; Mary Margaret Huizinga; Xulei Liu; Robert A Greevy; Carlos G Grijalva; Harvey J Murff; Adriana M Hung; Marie R Griffin Journal: Pharmacoepidemiol Drug Saf Date: 2010-11-12 Impact factor: 2.890
Authors: Donald K Ingram; Min Zhu; Jacek Mamczarz; Sige Zou; Mark A Lane; George S Roth; Rafael deCabo Journal: Aging Cell Date: 2006-04 Impact factor: 9.304
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin Journal: Ann Intern Med Date: 2012-11-06 Impact factor: 25.391
Authors: Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor Journal: Ageing Res Rev Date: 2015-10-14 Impact factor: 10.895
Authors: Sara E Espinoza; Nicolas Musi; Chen-Pin Wang; Joel Michalek; Beverly Orsak; Terry Romo; Becky Powers; Alice Conde; Melody Moris; Darcy Bair-Kelps; Yan Li; Vinutha Ganapathy; Tyson E Jergensen; Lauri C Kelly; Rozmin Jiwani Journal: J Gerontol A Biol Sci Med Sci Date: 2020-01-01 Impact factor: 6.053
Authors: Marta G Novelle; Ahmed Ali; Carlos Diéguez; Michel Bernier; Rafael de Cabo Journal: Cold Spring Harb Perspect Med Date: 2016-03-01 Impact factor: 6.915
Authors: Ariela R Orkaby; Lisa Nussbaum; Yuk-Lam Ho; David Gagnon; Lien Quach; Rachel Ward; Rachel Quaden; Enzo Yaksic; Kelly Harrington; Julie M Paik; Dae H Kim; Peter W Wilson; J Michael Gaziano; Luc Djousse; Kelly Cho; Jane A Driver Journal: J Gerontol A Biol Sci Med Sci Date: 2019-07-12 Impact factor: 6.053
Authors: Veronika Piskovatska; Nadiya Stefanyshyn; Kenneth B Storey; Alexander M Vaiserman; Oleh Lushchak Journal: Biogerontology Date: 2018-09-25 Impact factor: 4.277